ovarian
Hormone replacement therapy elevates ovarian cancer risk
February 13, 2015Research and Development, Sales and Marketing Cancer, HRT, Lancet, Oxford, oncology, ovarian
According to a new study women who undergo hormone replacement therapy nearly double their risk of developing ovarian cancer. Findings …
AstraZeneca ovarian cancer drug approved in Europe
December 18, 2014Sales and Marketing AstraZeneca, BRCA, Cambridge, Cancer, FDA, lynparza, olaparib, ovarian
The European Commission has approved AstraZeneca’s Lynparza for the treatment of advanced BRCA-mutated ovarian cancer. Lynparza (olaparib) has been approved …
AstraZeneca faces olaparib questions
June 24, 2014Manufacturing and Production, Research and Development, Sales and Marketing AstraZeneca, Cancer, FDA, olaparib, ovarian
AstraZeneca is facing questions from US regulators over the efficacy of one of its most promising late-stage treatments. Olaparib is …
Votrient’s extended licence application ditched
April 1, 2014Sales and Marketing EMA, Europe, GSK, ovarian, votrient kidney cancer
GlaxoSmithKline admits it is ‘disappointed’ after abandoning its attempt to extend kidney cancer drug Votrient’s licence to take in ovarian …
Avastin gains EU licence for ovarian cancer
January 3, 2012Sales and Marketing Roche, avastin, ovarian
Roche’s Avastin has been granted a new European licence to treat ovarian cancer, which could help offset falling sales of …
Avastin study in ovarian cancer meets primary endpoint
February 25, 2010Research and Development Cancer, avastin, ovarian
Preliminary results from a trial of Roche’s Avastin in advanced ovarian cancer suggest that the drug lengthens progression-free survival when …
Boehringer’s ovarian cancer drug enters phase III
December 18, 2009Research and Development, Sales and Marketing Boehringer, Cancer, ovarian
Boehringer Ingelheim has started a new phase III trial for its investigational cancer drug BIBF 1120. The LUME-Ovar-1 programme will …
Latest content
FibroFind appoints Lee Borthwick as CEO
